Interaction Checker

Wechselwirkungen von Glucagon

Glucagon (GlucaGen, Gvoke, Baqsimi) hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 132 dokumentierte Wechselwirkungen: 64 schwerwiegende, 43 mittelschwere, 25 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (64)

  • AclidiniumbromidAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • AmantadinAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Amitriptylintrizyklisches AntidepressivumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Amoxapintrizyklisches AntidepressivumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • AtropinAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Atropin und PralidoximAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Belladonna und OpiumOpioidSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • BenzatropinAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Brompheniramin, Pseudoephedrin und DextromethorphanAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • CarbinoxaminAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Chlordiazepoxid und ClidiniumbromidBenzodiazepinSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ChlorphenaminAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ChlorpromazinAntipsychotikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ClemastinAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Clomipramintrizyklisches AntidepressivumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ClozapinAntipsychotikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • CyclobenzaprinMuskelrelaxansSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • CyclopentolatAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • CyproheptadinAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • DarifenacinAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Desipramintrizyklisches AntidepressivumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • DexchlorpheniraminAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • DicycloverinAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • DimenhydrinatAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • DiphenhydraminAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • DisopyramidAntiarrhythmikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Doxepintrizyklisches AntidepressivumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • DoxylaminAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Doxylamin und PyridoxinAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ExenatidGLP-1-RezeptoragonistSchwerwiegend

    Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, including BYETTA [see Adverse Reactions (6.2) ] . (Fachinformation zu Exenatid, Warnhinweise und Vorsichtsmaßnahmen)

  • FesoterodinAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • FlavoxatAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • GlycopyrroniumbromidAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Hydrocodon und ChlorphenaminOpioidSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • HydroxyzinAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • HyoscyaminAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Imipramintrizyklisches AntidepressivumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • IpratropiumbromidAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Ipratropiumbromid und SalbutamolAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • MeclozinAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • MethylscopolaminAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Nortriptylintrizyklisches AntidepressivumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • OlanzapinAntipsychotikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Olanzapin und FluoxetinAntipsychotikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • OrphenadrinMuskelrelaxansSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Orphenadrin, Acetylsalicylsäure und KoffeinMuskelrelaxansSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • OxybutyninAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ParoxetinSSRISchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Phenobarbital, Hyoscyamin, Atropin und ScopolaminBarbituratSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ProchlorperazinAntipsychotikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • PromethazinAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Promethazin und CodeinOpioidSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Promethazin und DextromethorphanAntihistaminikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Protriptylintrizyklisches AntidepressivumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ScopolaminAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • SolifenacinAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ThioridazinAntipsychotikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • TiotropiumbromidAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • TolterodinAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • TrihexyphenidylAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Trimipramintrizyklisches AntidepressivumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • TrospiumchloridAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • UmeclidiniumbromidAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Umeclidiniumbromid und VilanterolAnticholinergikumSchwerwiegend

    Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

Mittelschwere Wechselwirkungen (43)

  • AcebutololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ApixabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • ArgatrobanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • AtenololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Atenolol und ChlortalidonBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • BetaxololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • BisoprololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Bisoprolol und HydrochlorothiazidBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • BivalirudinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Brimonidin und TimololAlpha-Adrenozeptor-AgonistMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • CarvedilolBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • DabigatranAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Dorzolamid und TimololCarboanhydrasehemmerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • EdoxabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • EnoxaparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • EsmololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • FondaparinuxAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • GlimepiridSulfonylharnstoffMittelschwer

    The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,… (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

  • GlipizidSulfonylharnstoffMittelschwer

    …glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

  • HeparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Humaninsulin (Normalinsulin)InsulinMittelschwer

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • IndometacinNSARMittelschwer

    Indomethacin Clincial Impact: In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Insulin aspartInsulinMittelschwer

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin degludecInsulinMittelschwer

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin detemirInsulinMittelschwer

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin glarginInsulinMittelschwer

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • Insulin lisproInsulinMittelschwer

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • LabetalolBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • LanreotidMittelschwer

    Hyperglycemia and Hypoglycemia Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. (Fachinformation zu Lanreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • MetoprololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Metoprolol und HydrochlorothiazidBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • NadololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • NebivololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • OctreotidMittelschwer

    Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

  • PhentolaminAlphablockerMittelschwer

    If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • PindololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • Pioglitazon und GlimepiridThiazolidindion (Glitazon)Mittelschwer

    The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,… (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

  • PropranololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • RivaroxabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • SotalolBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • TimololBetablockerMittelschwer

    Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

  • TirzepatidGLP-1-RezeptoragonistMittelschwer

    Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • WarfarinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Intervention Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required. (Fachinformation zu Glucagon, Arzneimittelwechselwirkungen)

Geringfügige Erwähnungen (25)

  • Azelastin und FluticasonAntihistaminikumGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • BeclometasonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • BetamethasonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • BudesonidKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • Budesonid und FormoterolKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • CiclesonidKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • ClobetasolKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • DeflazacortKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • DesonidKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • DexamethasonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • DulaglutidGLP-1-RezeptoragonistGeringfügig

    Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. (Fachinformation zu Dulaglutid, Warnhinweise und Vorsichtsmaßnahmen)

  • FludrocortisonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • FlunisolidKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • FluocinonidKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • FluticasonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • Fluticason und SalmeterolKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • HalobetasolKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • HydrocortisonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • MethylprednisolonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • MometasonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • Olopatadin und MometasonAntihistaminikumGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisolonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

  • RepaglinidGlinidGeringfügig

    Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

  • TriamcinolonKortikosteroidGeringfügig

    In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Fachinformation zu Glucagon, Warnhinweise und Vorsichtsmaßnahmen)

Prüfen Sie Glucagon gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.